LOW-GRADE INFLAMMATION IN MODERN CIVILIZATION DISEASES: A NARRATIVE REVIEW OF MECHANISMS, BIOMARKERS, AND CLINICAL IMPLICATIONS

Mateusz Mierniczek; Maria Mierniczek; Ewa Gloc; Dominika Dmowska; Paweł Zdebski; Aleksandra Bilińska; Kinga Kaczmarska; Kinga Rosołowska; Jarosław Dudek; Aleksandra Mierniczek

doi:10.31435/ijitss.4(48).2025.4444

Authors

Mateusz Mierniczek St. Raphael’s Voivodeship Specialist Hospital in Czerwona Góra, Chęciny, Poland https://orcid.org/0009-0009-9571-7859
Maria Mierniczek St. Raphael’s Voivodeship Specialist Hospital in Czerwona Góra, Chęciny, Poland https://orcid.org/0009-0000-9108-1552
Ewa Gloc Bonifrater Medical Center in Lodz, Lodz, Poland https://orcid.org/0009-0001-4293-750X
Dominika Dmowska HCP Medical Center, John Paul II Hospital, Poznań, Poland https://orcid.org/0009-0002-9269-5577
Paweł Zdebski Poznan University of Medical Sciences, Poznan, Greater Poland, Poland https://orcid.org/0009-0004-9718-157X
Aleksandra Bilińska Medical University of Łódź, Poland https://orcid.org/0009-0002-8833-6934
Kinga Kaczmarska Provincial Integrated Hospital, Kielce, Świętokrzyskie Voivodeship, Poland https://orcid.org/0009-0001-2468-430X
Kinga Rosołowska St. Raphael’s Voivodeship Specialist Hospital in Czerwona Góra, Chęciny, Poland https://orcid.org/0009-0003-7992-060X
Jarosław Dudek St. Raphael’s Voivodeship Specialist Hospital in Czerwona Góra, Chęciny, Poland https://orcid.org/0009-0005-1273-5682
Aleksandra Mierniczek MSWiA Hospital in Gdansk, Gdansk, Poland https://orcid.org/0009-0003-5596-2135

DOI:

https://doi.org/10.31435/ijitss.4(48).2025.4444

Keywords:

Low-grade Inflammation, NLRP3 Inflammasome, Evolutionary Mismatch, Biomarkers, suPAR, Colchicine, Immunometabolism

Abstract

Over the last century, the epidemiological landscape has shifted from acute infectious diseases to chronic non-communicable diseases (NCDs), including cardiovascular disease, type 2 diabetes, and neurodegeneration. These pathologies share a common, underlying biological substrate: chronic, low-grade inflammation, which is hypothesized to arise from an evolutionary mismatch between the human genome and the modern anthropogenic environment. This narrative review synthesizes evidence regarding the molecular mechanisms of sterile inflammation, emerging biomarkers, and therapeutic interventions by integrating data from immunology, metabolic medicine, and large-scale clinical trials. The analysis demonstrates that the pathology is driven by triggers such as metabolic surplus and oxidative stress, which activate the NLRP3 inflammasome and NF-κB pathways. This activation leads to reciprocal dysfunction between insulin signaling and endothelial integrity, creating a metabolic-vascular nexus that drives atherosclerosis, while gut dysbiosis and blood-brain barrier disruption extend this inflammation to the central nervous system, promoting neurodegeneration. While high-sensitivity CRP remains the standard biomarker, emerging markers like suPAR and GlycA offer superior stability and prognostic value. Therapeutically, the CANTOS and LoDoCo2 trials have validated the efficacy of targeting specific inflammatory pathways (IL-1β, NLRP3) over broad immunosuppression. Ultimately, low-grade inflammation is identified as the defining physiological signature of the modern age, serving as the "common soil" for multimorbidity. Effective management necessitates the adoption of a Personalized Immunometabolism framework, integrating biomarker-guided pharmacotherapy (e.g., colchicine) with lifestyle interventions that resolve the fundamental evolutionary mismatch, as future progress depends on bridging the gap between prognostic biomarkers and actionable clinical protocols.

References

Minihane, A. M., Vinoy, S., Russell, W. R., Baka, A., Roche, H. M., Tuohy, K. M., Teeling, J. L., Blaak, E. E., Fenech, M., Vauzour, D., McArdle, H. J., Kremer, B. H., Sterkman, L., Vafeiadou, K., Benedetti, M. M., Williams, C. M., & Calder, P. C. (2015). Low-grade inflammation, diet composition and health: current research evidence and its translation. The British journal of nutrition, 114(7), 999–1012. https://doi.org/10.1017/S0007114515002093

Furman, D., Campisi, J., Verdin, E., Carrera-Bastos, P., Targ, S., Franceschi, C., Ferrucci, L., Gilroy, D. W., Fasano, A., Miller, G. W., Miller, A. H., Mantovani, A., Weyand, C. M., Barzilai, N., Goronzy, J. J., Rando, T. A., Effros, R. B., Lucia, A., Kleinstreuer, N., & Slavich, G. M. (2019). Chronic inflammation in the etiology of disease across the life span. Nature medicine, 25(12), 1822–1832. https://doi.org/10.1038/s41591-019-0675-0

Pahwa R, Goyal A, Jialal I. Chronic Inflammation. [Updated 2023 Aug 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493173/

Malesza, I. J., Malesza, M., Walkowiak, J., Mussin, N., Walkowiak, D., Aringazina, R., Bartkowiak-Wieczorek, J., & Mądry, E. (2021). High-Fat, Western-Style Diet, Systemic Inflammation, and Gut Microbiota: A Narrative Review. Cells, 10(11), 3164. https://doi.org/10.3390/cells10113164

Ridker P. M. (2018). Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications. Circulation, 137(17), 1763–1766. https://doi.org/10.1161/CIRCULATIONAHA.117.033254

Berk, M., Williams, L. J., Jacka, F. N., O'Neil, A., Pasco, J. A., Moylan, S., Allen, N. B., Stuart, A. L., Hayley, A. C., Byrne, M. L., & Maes, M. (2013). So depression is an inflammatory disease, but where does the inflammation come from?. BMC medicine, 11, 200. https://doi.org/10.1186/1741-7015-11-200

Manus M. B. (2018). Evolutionary mismatch. Evolution, medicine, and public health, 2018(1), 190–191. https://doi.org/10.1093/emph/eoy023

Moustakli, E., Stavros, S., Katopodis, P., Skentou, C., Potiris, A., Panagopoulos, P., Domali, E., Arkoulis, I., Karampitsakos, T., Sarafi, E., Michaelidis, T. M., Zachariou, A., & Zikopoulos, A. (2025). Oxidative Stress and the NLRP3 Inflammasome: Focus on Female Fertility and Reproductive Health. Cells, 14(1), 36. https://doi.org/10.3390/cells14010036

Ferrucci, L., & Fabbri, E. (2018). Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nature reviews. Cardiology, 15(9), 505–522. https://doi.org/10.1038/s41569-018-0064-2

Luo, B., Li, B., Wang, W., Liu, X., Xia, Y., Zhang, C., Zhang, M., Zhang, Y., & An, F. (2014). NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PloS one, 9(8), e104771. https://doi.org/10.1371/journal.pone.0104771

Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019). The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. International journal of molecular sciences, 20(13), 3328. https://doi.org/10.3390/ijms20133328

Ridker P. M. (2016). From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circulation research, 118(1), 145–156. https://doi.org/10.1161/CIRCRESAHA.115.306656

Abderrazak, A., Syrovets, T., Couchie, D., El Hadri, K., Friguet, B., Simmet, T., & Rouis, M. (2015). NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox biology, 4, 296–307. https://doi.org/10.1016/j.redox.2015.01.008

Muniyappa, R., Chen, H., Montagnani, M., Sherman, A., & Quon, M. J. (2020). Endothelial dysfunction due to selective insulin resistance in vascular endothelium: insights from mechanistic modeling. American journal of physiology. Endocrinology and metabolism, 319(3), E629–E646. https://doi.org/10.1152/ajpendo.00247.2020

Kim, J. A., Montagnani, M., Koh, K. K., & Quon, M. J. (2006). Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation, 113(15), 1888–1904. https://doi.org/10.1161/CIRCULATIONAHA.105.563213

Muniyappa, R., & Quon, M. J. (2007). Insulin action and insulin resistance in vascular endothelium. Current opinion in clinical nutrition and metabolic care, 10(4), 523–530. https://doi.org/10.1097/MCO.0b013e32819f8ecd

Cersosimo, E., & DeFronzo, R. A. (2006). Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes/metabolism research and reviews, 22(6), 423–436. https://doi.org/10.1002/dmrr.634

Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011). Adipokines in inflammation and metabolic disease. Nature reviews. Immunology, 11(2), 85–97. https://doi.org/10.1038/nri2921

Redinger R. N. (2007). The pathophysiology of obesity and its clinical manifestations. Gastroenterology & hepatology, 3(11), 856–863.

Milanowski, J., Pawłowska, M., Woźniak, A., & Szewczyk-Golec, K. (2025). Summarizing the Role of Selected Adipokines in Parkinson’s Disease: What Is Known About Leptin, Adiponectin, Resistin, Visfatin, and Progranulin in Neurodegeneration? Molecules, 30(22), 4431. https://doi.org/10.3390/molecules30224431

Fantuzzi G. (2008). Adiponectin and inflammation: consensus and controversy. The Journal of allergy and clinical immunology, 121(2), 326–330. https://doi.org/10.1016/j.jaci.2007.10.018

Dullaart, R. P. F., Gruppen, E. G., Connelly, M. A., Otvos, J. D., & Lefrandt, J. D. (2015). GlycA, a biomarker of inflammatory glycoproteins, is more closely related to the leptin/adiponectin ratio than to glucose tolerance status. Clinical Biochemistry, 48(12), 811–814. https://doi.org/10.1016/j.clinbiochem.2015.05.001

Christ, A., Lauterbach, M., & Latz, E. (2019). Western Diet and the Immune System: An Inflammatory Connection. Immunity, 51(5), 794–811. https://doi.org/10.1016/j.immuni.2019.09.020

Kearns R. (2024). Gut-Brain Axis and Neuroinflammation: The Role of Gut Permeability and the Kynurenine Pathway in Neurological Disorders. Cellular and molecular neurobiology, 44(1), 64. https://doi.org/10.1007/s10571-024-01496-z

Zinöcker, M. K., & Lindseth, I. A. (2018). The Western Diet-Microbiome-Host Interaction and Its Role in Metabolic Disease. Nutrients, 10(3), 365. https://doi.org/10.3390/nu10030365

Rábago-Monzón, Á. R., Osuna-Ramos, J. F., Armienta-Rojas, D. A., Camberos-Barraza, J., Camacho-Zamora, A., Magaña-Gómez, J. A., & De la Herrán-Arita, A. K. (2025). Stress-Induced Sleep Dysregulation: The Roles of Astrocytes and Microglia in Neurodegenerative and Psychiatric Disorders. Biomedicines, 13(5), 1121. https://doi.org/10.3390/biomedicines13051121

Vanuytsel, T., van Wanrooy, S., Vanheel, H., Vanormelingen, C., Verschueren, S., Houben, E., Salim Rasoel, S., Tόth, J., Holvoet, L., Farré, R., Van Oudenhove, L., Boeckxstaens, G., Verbeke, K., & Tack, J. (2014). Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut, 63(8), 1293–1299. https://doi.org/10.1136/gutjnl-2013-305690

Rodiño-Janeiro, B. K., Alonso-Cotoner, C., Pigrau, M., Lobo, B., Vicario, M., & Santos, J. (2015). Role of Corticotropin-releasing Factor in Gastrointestinal Permeability. Journal of neurogastroenterology and motility, 21(1), 33–50. https://doi.org/10.5056/jnm14084

Brinkman, J. E., Reddy, V., & Sharma, S. (2024). Physiology of Sleep. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK279071/

Agorastos, A., & Chrousos, G. P. (2022). The neuroendocrinology of stress: The stress-related continuum of chronic disease. Molecular Psychiatry, 27(1), 502–513. https://doi.org/10.1038/s41380-021-01224-9

Mullington, J. M., Simpson, N. S., Meier-Ewert, H. K., & Haack, M. (2010). Sleep loss and inflammation. Best practice & research. Clinical endocrinology & metabolism, 24(5), 775–784. https://doi.org/10.1016/j.beem.2010.08.014

Spielman, L. J., Gibson, D. L., & Klegeris, A. (2018). Unhealthy gut, unhealthy brain: The role of the intestinal microbiota in neurodegenerative diseases. Neurochemistry international, 120, 149–163. https://doi.org/10.1016/j.neuint.2018.08.005

Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nature reviews. Neuroscience, 9(1), 46–56. https://doi.org/10.1038/nrn2297

Breit, S., Kupferberg, A., Rogler, G., & Hasler, G. (2018). Vagus Nerve as Modulator of the Brain-Gut Axis in Psychiatric and Inflammatory Disorders. Frontiers in psychiatry, 9, 44. https://doi.org/10.3389/fpsyt.2018.00044

Bonaz, B., Sinniger, V., & Pellissier, S. (2017). Vagus nerve stimulation: a new promising therapeutic tool in inflammatory bowel disease. Journal of internal medicine, 282(1), 46–63. https://doi.org/10.1111/joim.12611

Mulak, A., & Bonaz, B. (2015). Brain-gut-microbiota axis in Parkinson's disease. World journal of gastroenterology, 21(37), 10609–10620. https://doi.org/10.3748/wjg.v21.i37.10609

Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nature reviews. Neuroscience, 13(10), 701–712. https://doi.org/10.1038/nrn3346

Mora, S., Rifai, N., Buring, J. E., & Ridker, P. M. (2006). Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation, 114(5), 381–387. https://doi.org/10.1161/CIRCULATIONAHA.106.634089

Mayer, E. A., Nance, K., & Chen, S. (2022). The Gut-Brain Axis. Annual Review of Medicine, 73, 439–453. https://doi.org/10.1146/annurev-med-042320-014032

Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., Kazi, D. S., Kolte, D., Kumbhani, D. J., LoFaso, J., Mahtta, D., Mark, D. B., Minissian, M., Navar, A. M., Patel, A. R., Piano, M. R., … Peer Review Committee Members (2023). 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation, 148(9), e9–e119. https://doi.org/10.1161/CIR.0000000000001168

Ndrepepa, G., Braun, S., Tada, T., King, L., Cassese, S., Fusaro, M., Keta, D., Kastrati, A., & Schmidt, R. (2014). Comparative prognostic value of C-reactive protein & fibrinogen in patients with coronary artery disease. The Indian journal of medical research, 140(3), 392–400.

Eu Rasmussen, L. J. H., Petersen, J. E. V., & Eugen-Olsen, J. (2021). Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation. Frontiers in immunology, 12, 780641. https://doi.org/10.3389/fimmu.2021.780641

Petersen, J. E. V., Kallemose, T., Barton, K. D., Caspi, A., & Rasmussen, L. J. H. (2020). Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker of mortality in healthy, general and patient populations: protocol for a systematic review and meta-analysis. BMJ open, 10(7), e036125. https://doi.org/10.1136/bmjopen-2019-036125

Wisborg, F. D., El Caidi, N. O., Taraldsen, I. A., Tonning, S., Kandiah, A., El-Sheikh, M., Bahrami, H. S. Z., Andersen, O., Rasmussen, L. J. H., Hove, J., Dixen, U., & Grand, J. (2025). Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic biomarker in acutely admitted patients with atrial fibrillation. Journal of arrhythmia, 41(2), e70077. https://doi.org/10.1002/joa3.70077

Li, Y., Ding, Y., Zhao, Y., Gui, Y., Shen, Y., & Xiang, Q. (2022). Prognostic value of soluble urokinase-type plasminogen activator receptor in coronary artery disease: A meta-analysis. European journal of clinical investigation, 52(12), e13867. https://doi.org/10.1111/eci.13867

Otvos, J. D., Shalaurova, I., Wolak-Dinsmore, J., Connelly, M. A., Mackey, R. H., Stein, J. H., & Tracy, R. P. (2015). GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation. Clinical chemistry, 61(5), 714–723. https://doi.org/10.1373/clinchem.2014.232918

Joshi, A. A., Lerman, J. B., Aberra, T. M., Afshar, M., Teague, H. L., Rodante, J. A., Krishnamoorthy, P., Ng, Q., Aridi, T. Z., Salahuddin, T., Natarajan, B., Lockshin, B. N., Ahlman, M. A., Chen, M. Y., Rader, D. J., Reilly, M. P., Remaley, A. T., Bluemke, D. A., Playford, M. P., Gelfand, J. M., … Mehta, N. N. (2016). GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis. Circulation research, 119(11), 1242–1253. https://doi.org/10.1161/CIRCRESAHA.116.309637

Soehnlein, O., & Libby, P. (2021). Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nature reviews. Drug discovery, 20(8), 589–610. https://doi.org/10.1038/s41573-021-00198-1

Ridker P. M. (2019). Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. Circulation research, 124(3), 437–450. https://doi.org/10.1161/CIRCRESAHA.118.313129

Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X. F., Ireland, M. A., Lenderink, T., Latchem, D., Hoogslag, P., Jerzewski, A., Nierop, P., Whelan, A., Hendriks, R., Swart, H., Schaap, J., Kuijper, A. F. M., van Hessen, M. W. J., … LoDoCo2 Trial Investigators (2020). Colchicine in Patients with Chronic Coronary Disease. The New England journal of medicine, 383(19), 1838–1847. https://doi.org/10.1056/NEJMoa2021372

Tardif, J. C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., Berry, C., López-Sendón, J., Ostadal, P., Koenig, W., Angoulvant, D., Grégoire, J. C., Lavoie, M. A., Dubé, M. P., Rhainds, D., Provencher, M., … Roubille, F. (2019). Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. The New England journal of medicine, 381(26), 2497–2505. https://doi.org/10.1056/NEJMoa1912388

Diamantis, E., Kyriakos, G., Quiles-Sanchez, L. V., Farmaki, P., & Troupis, T. (2017). The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature. Current cardiology reviews, 13(3), 209–216. https://doi.org/10.2174/1573403X13666170426104611

Cameron, A. R., Morrison, V. L., Levin, D., Mohan, M., Forteath, C., Beall, C., McNeilly, A. D., Balfour, D. J., Savinko, T., Wong, A. K., Viollet, B., Sakamoto, K., Fagerholm, S. C., Foretz, M., Lang, C. C., & Rena, G. (2016). Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circulation research, 119(5), 652–665. https://doi.org/10.1161/CIRCRESAHA.116.308445

Walton, R. G., Dungan, C. M., Long, D. E., Tuggle, S. C., Kosmac, K., Peck, B. D., Bush, H. M., Villasante Tezanos, A. G., McGwin, G., Windham, S. T., Ovalle, F., Bamman, M. M., Kern, P. A., & Peterson, C. A. (2019). Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A randomized, double-blind, placebo-controlled, multicenter trial: The MASTERS trial. Aging cell, 18(6), e13039. https://doi.org/10.1111/acel.13039

Ratsika, A., Codagnone, M. C., O'Mahony, S., Stanton, C., & Cryan, J. F. (2021). Priming for Life: Early Life Nutrition and the Microbiota-Gut-Brain Axis. Nutrients, 13(2), 423. https://doi.org/10.3390/nu13020423

Singh B, Goyal A, Patel BC. C-Reactive Protein: Clinical Relevance and Interpretation. [Updated 2025 May 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441843/

Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., Michos, E. D., Miedema, M. D., Muñoz, D., Smith, S. C., Jr, Virani, S. S., Williams, K. A., Sr, Yeboah, J., & Ziaeian, B. (2019). 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 140(11), e596–e646. https://doi.org/10.1161/CIR.0000000000000678

Lawler, P. R., Bhatt, D. L., Godoy, L. C., Lüscher, T. F., Bonow, R. O., Verma, S., & Ridker, P. M. (2021). Targeting cardiovascular inflammation: next steps in clinical translation. European heart journal, 42(1), 113–131. https://doi.org/10.1093/eurheartj/ehaa099

US Preventive Services Task Force, Mangione, C. M., Barry, M. J., Nicholson, W. K., Cabana, M., Chelmow, D., Coker, T. R., Davis, E. M., Donahue, K. E., Jaén, C. R., Kubik, M., Li, L., Ogedegbe, G., Pbert, L., Ruiz, J. M., Stevermer, J., & Wong, J. B. (2022). Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA, 328(8), 746–753. https://doi.org/10.1001/jama.2022.13044

Hunter P. (2012). The inflammation theory of disease. The growing realization that chronic inflammation is crucial in many diseases opens new avenues for treatment. EMBO reports, 13(11), 968–970. https://doi.org/10.1038/embor.2012.142

Lieberman D. E. (2016). The Story of the Human Body: Evolution, Health and Disease. Family medicine, 48(10), 822–823.

Soysal, P., Stubbs, B., Lucato, P., Luchini, C., Solmi, M., Peluso, R., Sergi, G., Isik, A. T., Manzato, E., Maggi, S., Maggio, M., Prina, A. M., Cosco, T. D., Wu, Y. T., & Veronese, N. (2016). Inflammation and frailty in the elderly: A systematic review and meta-analysis. Ageing research reviews, 31, 1–8. https://doi.org/10.1016/j.arr.2016.08.006

Statovci, D., Aguilera, M., MacSharry, J., & Melgar, S. (2017). The Impact of Western Diet and Nutrients on the Microbiota and Immune Response at Mucosal Interfaces. Frontiers in immunology, 8, 838. https://doi.org/10.3389/fimmu.2017.00838

Brentano, F., Schorr, O., Ospelt, C., Stanczyk, J., Gay, R. E., Gay, S., & Kyburz, D. (2007). Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis and rheumatism, 56(9), 2829–2839. https://doi.org/10.1002/art.22833